BCM
NBIX icon

BluePath Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

BluePath Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-310
Closed -$34.9K – 247
2023
Q3 		$34.9K Buy
+310
New +$32.6K 0.03% 223

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BluePath Capital Management's NBIX Position: Q4 2023 in Review

BluePath Capital Management sold out of Neurocrine Biosciences (NBIX) in Q4 2023, closing a stake of 310 shares — an estimated $34.9K sold.

BluePath Capital Management first reported a position in NBIX in Q3 2023 and held it in 1 quarter. The position peaked at $34.9K in Q3 2023. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • BluePath Capital Management reported no remaining Neurocrine Biosciences position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 310 Neurocrine Biosciences shares in Q4 2023, an estimated $34.9K.
  • BluePath Capital Management first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Neurocrine Biosciences position peaked at $34.9K in Q3 2023.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.